JW신약

067290KOSDAQ

53.0 / 100

Reference Date: 2026-10-23

Financial Score24.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 32.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

JW Shinapharm primarily engages in the manufacturing and sales of pharmaceuticals, building a systematic sales network through joint marketing with JW Chungwa Pharmaceutical. Its subsidiary, JW Crigen, specializes in cell therapy products. In 2024, the company achieved consolidated sales of 93 billion won and an operating profit of 10 billion won. Key products include antifungal medications, dermatological treatments, and internal medicine drugs.

Number of Employees

173people

Average Salary

69.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.67Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

3.26Industry Average 1.200.0Point

2.7x industry avg (risky)

ROE

46.53Industry Average 8.007.0Point

5.8x industry avg (excellent)

Debt Ratio

5.17Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲25.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -11.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 2,370Won52-week high 3,71052-week low 1,294

1-month return0.0Point

1m -32.57% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0